{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:11:27Z","timestamp":1791983487679,"version":"4.4.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.breast.2018.03.009","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T20:18:02Z","timestamp":1522441082000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Personalized prevention in high risk individuals: Managing hormones and beyond"],"prefix":"10.1016","volume":"39","author":[{"given":"D. Gareth","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2018.03.009_bib1","series-title":"Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer","author":"McIntosh","year":"2004"},{"key":"10.1016\/j.breast.2018.03.009_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","article-title":"Autosomal dominant inheritance of early onset breast cancer","volume":"73","author":"Claus","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2018.03.009_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0959-8049(96)00082-2","article-title":"Cancer genetics clinics","volume":"32","author":"Evans","year":"1996","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.breast.2018.03.009_bib4","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2018.03.009_bib5","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1078-0432.CCR-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2018.03.009_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/82533","article-title":"High constant incidence in twins and other relatives of women with breast cancer","volume":"26","author":"Peto","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.breast.2018.03.009_bib7","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germline TP53 mutations in cancer families","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.breast.2018.03.009_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(03)12856-5","article-title":"Family history is predictive of pathogenic mutations in BRCA1, BRCA2 and TP53 with high penetrance in a population based study of very early onset breast cancer","volume":"361","author":"Lalloo","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.breast.2018.03.009_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/ng.586","article-title":"Genome-wide association study identifies five new breast cancer susceptibility loci","volume":"42","author":"Turnbull","year":"2010","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.breast.2018.03.009_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng.2563","article-title":"Large-scale genotyping identifies 41 new loci associated with breast cancer risk","volume":"45","author":"Michailidou","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cge.12035","article-title":"Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK","volume":"84","author":"Ingham","year":"2013","journal-title":"Clin Genet"},{"issue":"19","key":"10.1016\/j.breast.2018.03.009_bib12","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","article-title":"Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","volume":"32","author":"Kurian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2018.03.009_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10897-014-9695-6","article-title":"Cancer risk assessment using genetic panel testing: considerations for clinical application","volume":"23","author":"Hiraki","year":"2014","journal-title":"J\u00a0Genet Counsel"},{"issue":"11","key":"10.1016\/j.breast.2018.03.009_bib14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/ejhg.2016.57","article-title":"Sensitivity of BRCA1\/2 testing in high-risk breast\/ovarian\/male breast cancer families: little contribution of comprehensive RNA\/NGS panel testing","volume":"24","author":"Byers","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"23","key":"10.1016\/j.breast.2018.03.009_bib15","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2018.03.009_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1940-6207.CAPR-14-0037","article-title":"Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention","volume":"7","author":"Evans","year":"2014","journal-title":"Cancer Prev Res"},{"issue":"7","key":"10.1016\/j.breast.2018.03.009_bib17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/1940-6207.CAPR-11-0458","article-title":"Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: a new paradigm for cancer prevention","volume":"5","author":"Evans","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.breast.2018.03.009_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4881","article-title":"Improving classical breast cancer risk prediction with single nucleotide polymorphisms and mammographic density","author":"van Veen","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7148","key":"10.1016\/j.breast.2018.03.009_bib19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","article-title":"A\u00a0genome-wide association study identifies multiple novel breast cancer susceptibility loci","volume":"447","author":"Easton","year":"2007","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.breast.2018.03.009_bib20","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1158\/0008-5472.CAN-10-1907","article-title":"Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction","volume":"70","author":"Antoniou","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2018.03.009_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/jmedgenet-2016-104125","article-title":"The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study","volume":"54","author":"Evans","year":"2017","journal-title":"J\u00a0Med Genet"},{"issue":"7","key":"10.1016\/j.breast.2018.03.009_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw302","article-title":"Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kuchenbaecker","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/bjc.2013.747","article-title":"Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK","volume":"110","author":"Brentnall","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2018.03.009_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/nature24284","article-title":"Association analysis identifies 65 new breast cancer risk loci","author":"Michailidou","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.breast.2018.03.009_bib25","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/ng.3785","article-title":"Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer","volume":"49","author":"Milne","year":"2017","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13058-015-0653-5","article-title":"Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort","volume":"17","author":"Brentnall","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2018.03.009_bib27","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2018.03.009_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.breast.2018.03.009_bib29","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.2002.06.029","article-title":"American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition","volume":"20","author":"Chlebowski","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"9880","key":"10.1016\/j.breast.2018.03.009_bib30","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.breast.2018.03.009_bib31","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.breast.2018.03.009_bib32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9922","key":"10.1016\/j.breast.2018.03.009_bib33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.breast.2018.03.009_bib34","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.breast.2018.03.009_bib35","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/jnci\/djn153","article-title":"Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk","volume":"100","author":"Grady","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.breast.2018.03.009_bib36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"22","key":"10.1016\/j.breast.2018.03.009_bib37","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-012-2041-5","article-title":"Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene","volume":"134","author":"Powles","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.breast.2018.03.009_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.breast.2018.03.009_bib41","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial","volume":"286","author":"King","year":"2001","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"10.1016\/j.breast.2018.03.009_bib42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12282-015-0619-6","article-title":"Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis","volume":"22","author":"Xu","year":"2015","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2018.03.009_bib43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-014-3026-3","article-title":"Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"146","author":"Gronwald","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.breast.2018.03.009_bib44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bjc.6603042","article-title":"Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations","volume":"94","author":"Bramley","year":"2006","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/gcc.10321","article-title":"Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A","volume":"39","author":"Mote","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"issue":"25","key":"10.1016\/j.breast.2018.03.009_bib46","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2018.03.009_bib47","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2010.33.0258","article-title":"Benefit\/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older","volume":"2","author":"Freedman","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women's health initiative randomized clinical trials","volume":"1","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.breast.2018.03.009_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials","volume":"318","author":"Manson","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"issue":"2","key":"10.1016\/j.breast.2018.03.009_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.breast.2018.03.009_bib52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib53","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ncb3471","article-title":"Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive","volume":"19","author":"Fu","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"22","key":"10.1016\/j.breast.2018.03.009_bib54","first-page":"4987","article-title":"Dissociation between steroid receptor expression and cell proliferation in the human breast","volume":"57","author":"Clarke","year":"1997","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/0008-5472.CAN-16-2025","article-title":"Out-RANKing BRCA1 in mutation carriers","volume":"77","author":"Nolan","year":"2017","journal-title":"Cancer Res"},{"issue":"5804","key":"10.1016\/j.breast.2018.03.009_bib56","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1126\/science.1130471","article-title":"Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist","volume":"314","author":"Poole","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib57","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/ERC-11-0378","article-title":"Antiprogestins in breast cancer treatment: are we ready?","volume":"19","author":"Lanari","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.breast.2018.03.009_bib58","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","article-title":"Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer","volume":"17","author":"Veronesi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2018.03.009_bib59","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/JCO.2008.19.3797","article-title":"Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women","volume":"27","author":"Decensi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2018.03.009_bib60","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence","volume":"60","author":"Heckman-Stoddard","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv006","article-title":"Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32","volume":"107","author":"Goodwin","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.breast.2018.03.009_bib62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/BD-2010-0324","article-title":"Bisphosphonates and breast cancer incidence and recurrence","volume":"33","author":"Chlebowski","year":"2011","journal-title":"Breast Dis"},{"issue":"10","key":"10.1016\/j.breast.2018.03.009_bib63","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2014.3634","article-title":"Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid","volume":"174","author":"Hue","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.breast.2018.03.009_bib64","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/bjc.2014.109","article-title":"Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic","volume":"110","author":"Donnelly","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2018.03.009_bib65","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2018.03.009_bib66","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2018.03.009_bib67","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13058-014-0442-6","article-title":"The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services","volume":"16","author":"Evans","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2018.03.009_bib68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2018.03.009_bib69","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2018.03.009_bib70","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Reduction in cancer risk after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","article-title":"Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer","volume":"140","author":"Evans","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2018.03.009_bib72","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10549-013-2765-x","article-title":"Risk-reducing surgery increases survival in BRCA1\/2 mutation carriers unaffected at time of family referral","volume":"142","author":"Ingham","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2018.03.009_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw177","article-title":"Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kotsopoulos","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib76","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-2407-8-155","article-title":"Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting","volume":"8","author":"Evans","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2018.03.009_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study","author":"Rosenthal","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2018.03.009_bib78","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jmedgenet-2013-101607","article-title":"Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2","volume":"50","author":"Ingham","year":"2013","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.breast.2018.03.009_bib79","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","article-title":"Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)","volume":"365","author":"Leach","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib80","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10549-014-2931-9","article-title":"MRI breast screening in high-risk women: cancer detection and survival analysis","volume":"145","author":"Evans","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2018.03.009_bib81","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/fon.10.27","article-title":"PARP inhibitors in BRCA1-\/BRCA2-associated and triple-negative breast cancers","volume":"6","author":"Stebbing","year":"2010","journal-title":"Future Oncol"},{"issue":"31","key":"10.1016\/j.breast.2018.03.009_bib82","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2018.03.009_bib83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","article-title":"Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study","volume":"155","author":"Kotsopoulos","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/COC.0000000000000269","article-title":"Is hormone replacement therapy safe in women with a BRCA mutation?: a systematic review of the contemporary literature","volume":"41","author":"Birrer","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"31","key":"10.1016\/j.breast.2018.03.009_bib85","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2008.21.6432","article-title":"Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?","volume":"27","author":"Fournier","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2018.03.009_bib86","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1055-9965.EPI-06-0034","article-title":"Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis","volume":"15","author":"McCormack","year":"2006","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"10.1016\/j.breast.2018.03.009_bib87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10549-010-0749-7","article-title":"Mammographic density does not differ between unaffected BRCA1\/2 mutation carriers and women at low-to-average risk of breast cancer","volume":"123","author":"Gierach","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.breast.2018.03.009_bib88","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1200\/JCO.2009.27.5933","article-title":"Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?","volume":"28","author":"Passaperuma","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib89","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1158\/0008-5472.CAN-05-3368","article-title":"Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"66","author":"Mitchell","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2018.03.009_bib90","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/jnci\/djr079","article-title":"Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study","volume":"103","author":"Cuzick","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.breast.2018.03.009_bib91","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/tbj.12002","article-title":"Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging","volume":"18","author":"King","year":"2012","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2018.03.009_bib92","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10549-014-3175-4","article-title":"A\u00a0polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2","volume":"149","author":"Vachon","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.breast.2018.03.009_bib93","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1200\/JCO.2016.69.8944","article-title":"Impact of a panel of 88 single nucleotide polymorphisms on the risk of breast cancer in high-risk women: results from two randomized tamoxifen prevention trials","volume":"35","author":"Cuzick","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2018.03.009_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007031","article-title":"SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER\u03b1-positive breast cancer through regulation of BRCA1","volume":"13","author":"Cairns","year":"2017","journal-title":"PLoS Genet"},{"issue":"3","key":"10.1016\/j.breast.2018.03.009_bib95","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-016-3885-x","article-title":"Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials","volume":"158","author":"Brentnall","year":"2016","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977618300572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977618300572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:40:27Z","timestamp":1760776827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977618300572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":95,"alternative-id":["S0960977618300572"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2018.03.009","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized prevention in high risk individuals: Managing hormones and beyond","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2018.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}